Market closedNon-fractional
Krystal Biotech/KRYS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Krystal Biotech
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Ticker
KRYS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Pittsburgh, United States
Employees
229
Website
www.krystalbio.com
Krystal Biotech Metrics
BasicAdvanced
$6B
Market cap
105.97
P/E ratio
$1.99
EPS
0.90
Beta
-
Dividend rate
Price and volume
Market cap
$6B
Beta
0.9
Financial strength
Current ratio
12.655
Quick ratio
12.287
Long term debt to equity
0.809
Total debt to equity
0.988
Management effectiveness
Return on assets (TTM)
-4.97%
Return on equity (TTM)
8.87%
Valuation
Price to earnings (TTM)
105.97
Price to revenue (TTM)
61.045
Price to book
7.41
Price to tangible book (TTM)
7.41
Price to free cash flow (TTM)
-107.593
Growth
Earnings per share change (TTM)
-137.68%
3-year earnings per share growth (CAGR)
-2.69%
What the Analysts think about Krystal Biotech
Analyst Ratings
Majority rating from 10 analysts.
Krystal Biotech Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$45M
7.36%
Net income
$900K
-89.53%
Profit margin
1.99%
-90.25%
Krystal Biotech Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.25
$2.79
$0.30
$0.03
-
Expected
-$0.74
-$0.29
-$0.43
$0.15
$0.62
Surprise
69.68%
-1,075.52%
-170.59%
-79.61%
-
Krystal Biotech News
AllArticlesVideos
Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024
GlobeNewsWire·15 hours ago
Krystal Biotech to Present at the American Thoracic Society 2024 International Conference
GlobeNewsWire·2 months ago
Krystal Biotech to Present at BofA Securities 2024 Health Care Conference
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Krystal Biotech stock?
Krystal Biotech (KRYS) has a market cap of $6B as of July 27, 2024.
What is the P/E ratio for Krystal Biotech stock?
The price to earnings (P/E) ratio for Krystal Biotech (KRYS) stock is 105.97 as of July 27, 2024.
Does Krystal Biotech stock pay dividends?
No, Krystal Biotech (KRYS) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Krystal Biotech dividend payment date?
Krystal Biotech (KRYS) stock does not pay dividends to its shareholders.
What is the beta indicator for Krystal Biotech?
Krystal Biotech (KRYS) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Krystal Biotech stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.